8-K: Cellectar Biosciences Announces First Quarter 2025 Financial Results and Strategic Review

Cellectar Biosciences reported its Q1 2025 financial results, announced a strategic review process, and is seeking conditional approval from the EMA for Iopofosine I 131 in Waldenstrom Macroglobulinemia.

Summary

• Cellectar Biosciences announced its financial results for the quarter ended March 31, 2025, and provided a corporate update.
• The company is seeking conditional approval from the European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based on Phase 2 CLOVER WaM study data.
• The CLOVER WaM study showed a major response rate of 59.0% for BTKi-treated patients.
• Cellectar plans to present the CLOVER WaM data to the EMA in the second quarter of 2025 and anticipates a response regarding the regulatory pathway before the end of the third quarter of 2025.
• The company is exploring strategic alternatives, including mergers, acquisitions, partnerships, joint ventures, and licensing arrangements, and has engaged Oppenheimer & Co. Inc. as its exclusive financial advisor.
• A Phase 3 study for Iopofosine I 131 in relapsed/refractory Waldenstrom macroglobulinemia is planned as a comparator, randomized controlled study with 100 patients per arm, contingent on additional funding or a strategic collaboration.
• A Phase 1b/2a dose-finding study for CLR 121125 in triple-negative breast cancer is planned, funding dependent.
• Pre-clinical studies evaluating CLR 121225 in refractory pancreatic models showed desired pharmacokinetics, biodistribution, and activity.
• As of March 31, 2025, Cellectar had $13.9 million in cash and cash equivalents, compared to $23.3 million as of December 31, 2024.
• The company believes its cash balance is adequate to fund basic budgeted operations into the fourth quarter of 2025.
• Research and development expenses for the three months ended March 31, 2025, were approximately $3.4 million, compared to $7.1 million for the same period in 2024.
• General and administrative expenses for the three months ended March 31, 2025, were approximately $3.0 million, compared to $4.9 million for the same period in 2024.
• The net loss attributable to common stockholders for the three months ended March 31, 2025, was $6.6 million, or $0.14 per share, compared to $26.6 million, or $0.91 per share in the three months ended March 31, 2024.

Sentiment

Score: 5

Explanation: The announcement contains both positive and negative elements. The potential EMA approval and pipeline progress are positive, but the limited cash runway and strategic review introduce uncertainty.

Positives

• The Phase 2 CLOVER WaM clinical trial data for Iopofosine I 131 are considered impressive.
• The company is actively seeking conditional marketing approval from the EMA.
• Cellectar has a pipeline of radiotherapeutic candidates, including alphaand Auger-emitting radioconjugates, with observed preclinical activity in solid tumor models.
• Research and development expenses decreased significantly year-over-year.
• General and administrative expenses decreased significantly year-over-year.
• The net loss decreased significantly year-over-year.

Negatives

• The company needs to gather additional clinical data for Iopofosine I 131.
• Initiation of the Phase 3 study for Iopofosine I 131 is dependent on obtaining additional funding or a strategic collaboration.
• Initiation of the Phase 1b/2a dose-finding study for CLR 121125 is funding dependent.
• Cash reserves are only expected to fund operations into the fourth quarter of 2025.

Risks

• The company's ability to obtain conditional marketing approval from the EMA is uncertain.
• The strategic review process may not result in a favorable outcome.
• The company may not be able to secure additional funding or a strategic collaboration to advance its clinical programs.
• The company's cash reserves may not be sufficient to fund its operations beyond the fourth quarter of 2025.
• Drug development involves a high degree of risk, and clinical trials may not be successful.

Future Outlook

The company is focused on obtaining conditional approval from the EMA for Iopofosine I 131, advancing its pipeline of radiotherapeutic candidates, and exploring strategic alternatives to secure additional funding.

Management Comments

• We plan to present these data to the EMA during the second quarter of 2025 as part of the registration package seeking conditional marketing approval.
• We anticipate a response regarding the regulatory pathway from the European agency before the end of the third quarter of this year, said James Caruso, president and CEO of Cellectar.
• With cash into the fourth quarter of this year we are evaluating a variety of funding pathways to successfully advance our novel pipeline assets.

Industry Context

Cellectar's focus on radiopharmaceutical therapeutics aligns with a growing trend in cancer treatment, with increasing interest in targeted therapies that deliver radiation directly to cancer cells. The company's strategic review also reflects the challenges faced by many small biotech companies in securing funding and advancing their pipelines.

Comparison to Industry Standards

• The 59% major response rate in BTKi-treated patients in the CLOVER WaM study is a notable result, potentially competitive with other therapies for Waldenstrom Macroglobulinemia.
• Companies like Novartis and Bayer are also investing heavily in radiopharmaceutical therapies, indicating the potential of this approach.
• The company's cash runway into Q4 2025 is relatively short compared to industry standards, where companies typically aim for at least 12-18 months of cash reserves.

Stakeholder Impact

• Shareholders face uncertainty due to the strategic review and limited cash runway.
• Employees may be affected by potential restructuring or strategic changes.
• Patients could benefit from the potential approval and development of new cancer treatments.
• Partners and collaborators may be impacted by the strategic review process.

Next Steps

• Present CLOVER WaM data to the EMA in Q2 2025.
• Await EMA response regarding regulatory pathway by the end of Q3 2025.
• Continue exploring strategic alternatives.
• Seek additional funding or a strategic collaboration to initiate the Phase 3 study for Iopofosine I 131.
• Potentially initiate a Phase 1b/2a dose-finding study for CLR 121125, funding dependent.

Key Dates

Keywords

Cellectar Biosciences, Iopofosine I 131, Waldenstrom Macroglobulinemia, Radiopharmaceutical, Clinical Trial, EMA, Strategic Alternatives, Financial Results, CLR 121125, CLR 121225